Auto-Immune Cardiac Degeneration as a Complication of Essential Hypertension

Main Article Content

Odewusi, O.O.
Olaifa B.A.
Bamishaye D.A.
Omon E.A.
Ogunfolakan O.O.
Oguntase, M.O.
Alake, O.A.
Akindele, O.A.

Abstract

Essential hypertension is persistent high blood pressure in the systemic arteries with no identifiable secondary cause. The study was designed to assess auto-immune cardiac degeneration in essential hypertensive patients in Ekiti State. The study included 40 subjects with no history of hypertension (control), 40 hypertensive subjects undergoing treatment and 40 hypertensive subjects without treatment. Body Mass Index (BMI) was calculated, systolic and diastolic blood pressure (SBP and DBP) readings were taken using digital sphygmomanometer, Aspartate Aminotransferase (AST) was measured using spectrophotometer, Cardiac Troponin (CTnI) and Anti-mitochondrial antibody M7 (AMA-M7) were estimated using ELISA. Results obtained were expressed as mean ± SD and statistical analysis was done using SPSS. Values were statistically significant at p<0.05. The results obtained showed that BMI and DBP of treated hypertensive patient was insignificant when compared with control subjects (p>0.05), whereas SBP, AST, AMA-M7 and CTnI were significantly higher (p<0.05) in treated hypertensive patients compared with the control subjects. Similarly, BMI, SBP, DBP, AMA-M7, AST and CTnI of untreated hypertensive patient were significantly higher (p<0.05) compared with non-hypertensive subjects (control). Furthermore, BMI, SBP, DBP, AMA-M7, AST and CTnI were significantly lower (p<0.05) in treated hypertensive patient compared with untreated hypertensive subjects. In conclusion, AMA-M7 is more sensitive marker in detecting auto-immune cardiac degeneration faster than the routine serum AST and Cardiac Troponin I in indicating the functional state of the heart. Therefore, early detection of auto-immune cardiac degeneration in hypertension subjects is important as there is a link between autoimmunity and hypertension.

Article Details

How to Cite
Odewusi, O.O., Olaifa B.A., Bamishaye D.A., Omon E.A., Ogunfolakan O.O., Oguntase, M.O., Alake, O.A., & Akindele, O.A. (2024). Auto-Immune Cardiac Degeneration as a Complication of Essential Hypertension. International Journal of Pharmaceutical and Bio Medical Science, 4(2), 97–104. https://doi.org/10.47191/ijpbms/v4-i2-10
Section
Articles

References

I. Iqbal, A.M. and Jamal, S.F. (2023): Essential Hypertension. In: StatPearls Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539859/

II. Avinas, R., Megumi, N., Ping, L., Limei, P., Yanglong, L., Guang, Y. and Xian, W. (2020): Adaptive immune disorders in hypertension and heart failure: focusing onT-cell subset activation and clinical implications. Journal of Hypertension, 38: 1878-1889.

III. World Health Organization (2019): Cardiovascular diseases (2019). New initiative launched to tackle cardiovascular disease, the world’s number one killer.http://www.who.int/cardiovascular_diseases/en/ (23 July 2023).

IV. Forouzanfar, M.H., Liu, P. and Roth, G.A. (2017): Global burden of hypertension and systolic blood pressure of at least 110 to 115 mmHg, 1990–2015. JAMA, 317(2): 165-182.

V. Solak, Y., Baris, A., Nosratola, D.V., Gamze, A., Can, E.Y., Adrian, C. and Mehmet, K. (2016): Hypertension as an autoimmune and inflammatory Disease. Journal of Japanese Hypertension Research, 39: 567–573.

VI. Liu, C., Rodney, E.K. and Yang, X. (2017). Inflammation, Autoimmunity, and Hypertension: The Essential Role of Tissue Transglutaminase. American Journal of Hypertension. 30(8): 756-764.

VII. Caillon, A. and Schiffrin, E.L. (2016): Role of inflammation and immunity in hypertension: recent epidemiological, laboratory, and clinical evidence. Curr Hypertens Rep. 18: 21-24.

VIII. Becker, Y., Loignon, R.C. and Julien, A.S. (2019): Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations. Sci Rep. 9: 4530-4533

IX. Chan, C.T., Sobey, C.G., Lieu, M., Ferens, D., Kett, M.M., Diep, H., Kim, H.A., Krishnan, S.M., Lewis, C.V., Salimova, E., Tipping, P., Vinh, A., Samuel, C.S., Peter, K., Guzik, T.J., Kyaw, T.S., Toh, B.H., Bobik, A. and Drummond, G.R. (2015): Obligatory role for B cells in the development of angiotensin II-dependent hypertension. Hypertension, 66: 1023-1033.

X. Colapietro, F., Lleo, A. and Generali, E. (2022): Antimitochondrial Antibodies: from Bench to Bedside. Clinical Reviews in Allergy & Immunology, 63: 166–177.

XI. Santos-Moreno, P., Burgos-Angulo, G. and Martinez-Ceballos, M.A. (2021): Inflammaging as a link between autoimmunity and cardiovascular disease: the case of rheumatoid arthritis. RMD Open, 7: 1470-1473.

XII. Schmidt, B.M., Durao, S., Toews, I., Bavuma, C.M., Hohlfeld, A., Nury, E., Meerpohl, J.J. and Kredo, T. (2020: Screening strategies for hypertension. Cochrane Database Syst Rev. 5(5): 13212.

XIII. Odewusi, O.O. and Osadolor, H.B. (2019): Interleukin 10 And 18 Levels in Essential Hypertension. Journal of Applied Sciences and Environmental Management. 23 (5) 819-824.

XIV. Landi, F., Calvani, R., Picca, A., Tosato, M., Martone, A.M., Ortolani, E., Sisto, A., D'Angelo, E., Serafini, E., Desideri, G., Fuga, M.T. and Marzetti, E. (2018): Body Mass Index is Strongly Associated with Hypertension: Results from the Longevity Check-up 7+ Study. Nutrients. 10(12): 1976.

XV. El-Meouchy, P., Wahoud, M., Allam, S., Chedid, R., Karam, W. and Karam, S. (2022): Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control. Int J Mol Sci. 23(20): 12305-12308.

XVI. Vrettos, I., Voukelatou, P., Pappa, E., Beletsioti, C., Papadopoulos, A. and Niakas, D. (2020): Increased Body Mass Index and Hypertension: An Unbreakable Bond. Int J Prev Med. 11:155.

XVII. Tan, J.L. and Thakur, K. (2023): Systolic Hypertension. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-.Available from:

https://www.ncbi.nlm.nih.gov/books/NBK482472/

XVIII. Zou, G., Witter, S., Caperon, L., Walley, J., Cheedella, K., Senesi, R. and Wurie, H. (2020): Adapting and implementing training, guidelines and treatment cards to improve primary care-based hypertension and diabetes management in a fragile context: results of a feasibility study in Sierra Leone. BMC Public Health. 20: 156-158.

XIX. Chang, H.K., Jeonggyu, K., Ara, C., Yoosoo, C., Seungho, R. and Ki-Chul, S. (2019): Optimal Target Blood Pressure and Risk of Cardiovascular Disease in Low-Risk Younger Hypertensive Patients. American Journal of Hypertension, 32(9): 833-841

XX. Cao, C., Hu, H. and Han, Y. (2023). The nonlinear correlation between alanine aminotransferase to high-density lipoprotein cholesterol ratio and the risk of diabetes: a historical Japanese cohort study. BMC Endocr Disord. 124(23): 452-458.

XXI. Xia, Y. and Kellems, R.E. (2019): Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond. Circ Research. 113: 78–87.

XXII. Lan, Q., Zhang, Y., Lin, F., Meng, Q., Buys, N.J., Fan, H. and Sun, J. (2022): Association Between Serum Aminotransferases and Risk of New-Onset Cardiometabolic Disease in a Healthy Chinese Population: A Cohort Study. Front Public Health. 10:902393.

XXIII. Rahman, S., Islam, S., Haque, T., Kathak, R.R. and Ali, N. (2020): Association between serum liver enzymes and hypertension: a cross-sectional study in Bangladeshi adults. BMC Cardiovasc Disorders. 20(1):128-130.

XXIV. Sakboonyarat, B., Poovieng, J. and Lertsakulbunlue, S. (2023): Association between raised blood pressure and elevated serum liver enzymes among active-duty Royal Thai Army personnel in Thailand. BMC Cardiovasc Disord. 143 (23): 2023-2028.

XXV. Pattanshetty, D.J., Bhat, P.K., Aneja, A. and Pillai, D.P. (2012): Elevated troponin predicts long-term adverse cardiovascular outcomes in hypertensive crisis: a retrospective study. Journal of Hypertension. 30(12): 2410-2415.

XXVI. Sternberg, M., Pasini, E., Chen-Scarabelli, C., Corsetti, G., Patel, H., Linardi, D., Onorati, F., Faggian, G., Scarabelli, T. and Saravolatz, L. (2019): Elevated Cardiac Troponin in Clinical Scenarios Beyond Obstructive Coronary Artery Disease. Med Sci Monit. 25:7115-7125.

XXVII. Kim, W., Kim, B.S., Kim, H.J., Lee, J.H., Shin, J. and Shin, J.H. (2022): Clinical implications of cardiac troponin-I in patients with hypertensive crisis visiting the emergency department. Ann Med. 54(1): 507-515.

XXVIII. Thygesen, K., Alpert, J.S. and Jaffe, A.S. (2018): Fourth universal definition of myocardial infarction Circulation. 138(20): 618–651.

XXIX. Wolf, V.L. and Ryan, M.J. (2019): Autoimmune Disease-Associated Hypertension. Curr Hypertension Report. 21(1):10-14.

XXX. Yokokawa, T., Yoshihisa, A., Misaka, T., Sato, T., Kaneshiro, T., Oikawa, M., Kobayashi, A., Yamaki, T., Kunii, H. and Takeishi, Y. (2021): Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy. Intern Med. 60(2):201-208.

Most read articles by the same author(s)